10-K: Inhibikase Therapeutics Outlines Ethical Standards and Provides Business Update

Inhibikase Therapeutics releases its Code of Business Conduct and Ethics while also providing an update on clinical trials and financial status.

Summary

• Inhibikase Therapeutics has released its Code of Business Conduct and Ethics, outlining standards for all employees, officers, and directors.
• The company is focused on developing protein kinase inhibitor therapeutics, particularly Risvodetinib, for neurodegenerative diseases like Parkinson's and Multiple System Atrophy (MSA).
• A Phase 2 trial for Risvodetinib in Parkinson's disease is underway with 32 active sites and 73 participants enrolled, with results expected in the second half of 2024.
• An extension of the Phase 2 trial by 12 months is planned, subject to additional resources, to further evaluate clinical benefits.
• Early data from 11 patients in the Phase 2 trial showed a -8.7 point improvement in the MDS-UPDRS Part II+III score for the 200mg dose group compared to a +1.7 point increase in the placebo group.
• Risvodetinib has received Orphan Drug Designation for MSA, and a Phase 2 study in MSA patients is planned across 19 EU and 6 US sites, involving at least 120 patients.
• The company is also developing IkT-001Pro, a prodrug of imatinib for stable phase Chronic Myelogenous Leukemia (CML), and has completed a bioequivalence study.
• A Pre-NDA meeting with the FDA indicated that the 505(b)(2) pathway is appropriate for IkT-001Pro approval, with further studies needed to evaluate gut absorption and higher doses.
• A tablet formulation of Risvodetinib has been developed, which nearly doubles the concentration delivered compared to the capsule form.
• The company has secured multiple NIH grants totaling over $10 million to support its research and development efforts.
• The company has worldwide commercialization rights to all of its development programs and IP protection until 2033 for IkT-001Pro and 2036 for Risvodetinib (IkT-148009).

Sentiment

Score: 7

Explanation: The document presents a positive outlook with promising early clinical data and strategic advancements, but also acknowledges significant risks and financial challenges. The sentiment is cautiously optimistic.

Positives

• The company has a clear focus on disease-modifying treatments for neurodegenerative diseases.
• The Phase 2 trial for Risvodetinib in Parkinson's disease is progressing with increasing enrollment.
• Early data from the Phase 2 trial suggests a potential clinical benefit of Risvodetinib.
• The company has received Orphan Drug Designation for Risvodetinib in MSA, which provides market exclusivity.
• The company has a prodrug technology that may improve drug absorption and reduce side effects.
• The company has a tablet formulation of Risvodetinib that improves drug delivery.
• The company has secured significant non-dilutive funding through NIH grants.
• The company has worldwide commercialization rights to all of its development programs and IP protection until 2033 for IkT-001Pro and 2036 for Risvodetinib (IkT-148009).

Negatives

• The company has a limited operating history and no products approved for commercial sale.
• The company has incurred significant net losses since its inception and anticipates continuing to incur net losses.
• The company is dependent on the success of its initial product candidates targeting neurodegenerative diseases.
• The company relies on third-party contract manufacturers and research institutions.
• The company may encounter substantial delays in its current and planned clinical trials.
• The company may not be able to obtain and maintain patent protection for its product candidates.
• The company may be subject to further clinical holds by the FDA in the future.

Risks

• The company may not be able to raise additional capital, which could limit future clinical trials and product development.
• The company may be subject to further clinical holds by the FDA.
• Clinical trials may reveal significant adverse events, toxicities, or other side effects.
• The company may encounter substantial delays in its current and planned clinical trials.
• The company may not be able to establish sales and marketing capabilities or enter into agreements with third parties.
• The company may be subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives.
• The company may be unable to obtain and maintain patent protection for its product candidates.
• The company is dependent on third-party suppliers for key raw materials.
• The company is subject to risks associated with conducting business internationally.

Future Outlook

The company plans to extend the Phase 2 trial for Risvodetinib by 12 months, initiate a Phase 2 study in MSA patients, submit regulatory documents for Risvodetinib to EU authorities in 2024, and continue preclinical studies for IkT-001Pro.

Management Comments

• The company strives to foster a culture of honesty and accountability.
• The company is strongly committed to conducting its business affairs with honesty and integrity and in full compliance with all applicable laws, rules and regulations.
• The company believes that its approach to neurodegenerative disease is validated by its 2022 and 2023 publications and oral presentations at the major academic and industry conferences in Parkinsons and Alzheimers diseases.
• The company believes that the application of these principles will significantly increase the probability of our success and will shorten the time required to bring effective therapeutics to patients with neurodegenerative and other diseases.

Industry Context

The company is operating in the competitive pharmaceutical industry, particularly in the neurodegenerative disease field, which has seen limited success in drug development. The company is differentiating itself by focusing on disease modification rather than symptom management and by using its RAMP technology to design novel molecules.

Comparison to Industry Standards

• The company's approach to neurodegenerative diseases differs from many competitors who focus on plaque removal, instead targeting dysfunctional proteins and their pathways.
• The company's RAMP technology, which uses approved drugs as templates for novel drug design, is a unique approach compared to traditional drug discovery methods.
• The company's focus on both brain and gastrointestinal tract manifestations of Parkinson's disease is a novel approach compared to other companies.
• The company's use of a prodrug technology to improve drug absorption and reduce side effects is a differentiating factor compared to other companies developing kinase inhibitors.
• The company's approach to c-Abl inhibition is similar to other companies such as Sun Pharma Advanced Research Company Ltd. (SPARC) and 1st Biotherapeutics, Inc., but the company is using a novel molecule with a different safety profile.
• The company's approach to drug delivery using a tablet formulation is similar to other companies, but the company has demonstrated a significant increase in drug concentration compared to the capsule form.

Management Changes

Related Party Transactions

• During the years ended December 31, 2023 and 2022 the company incurred expenses of approximately $ 33 thousand and $ 23 thousand, respectively with a related party vendor included in research and development expenses.
• As at the years ended December 31, 2023 and 2022 the company had a payable balance with a related party vendor of approximately $ 14 thousand and $ 16 thousand, respectively included in accounts payable.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees are subject to a code of conduct and ethics.
• Patients may benefit from the development of new treatments for neurodegenerative diseases.
• Creditors may be impacted by the company's ability to raise additional capital.

Next Steps

• Extend the Phase 2 trial for Risvodetinib by 12 months.
• Initiate a Phase 2 study in MSA patients across 19 EU and 6 US sites.
• Submit regulatory documents for Risvodetinib to EU authorities in 2024.
• Continue preclinical studies for IkT-001Pro, including evaluating gut absorption and higher doses.
• Request milestone-based meetings with the FDA Review Team as manufacturing and quality control processes are completed.

Key Dates

Keywords

Risvodetinib, Parkinson's disease, Multiple System Atrophy, IkT-001Pro, Chronic Myelogenous Leukemia, neurodegenerative diseases, clinical trials, drug development, protein kinase inhibitors, orphan drug designation, FDA, bioequivalence, prodrug technology, intellectual property, NIH grants